The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Open accessAbstract
BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear. METHODS: (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes) and invasive cancer of any type. Secondary end points included individual components of the composite cardiovascular end point, the composite end point plus coronary revascularization (expanded composite of cardiovascular events), site-specific cancers, and death from cancer. Safety was also assessed. This article reports the results of the comparison of n-3 fatty acids with placebo. RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Invasive cancer was diagnosed in 820 participants in the n-3 group and in 797 in the placebo group (hazard ratio, 1.03; 95% CI, 0.93 to 1.13; P=0.56). In the analyses of key secondary end points, the hazard ratios were as follows: for the expanded composite end point of cardiovascular events, 0.93 (95% CI, 0.82 to 1.04); for total myocardial infarction, 0.72 (95% CI, 0.59 to 0.90); for total stroke, 1.04 (95% CI, 0.83 to 1.31); for death from cardiovascular causes, 0.96 (95% CI, 0.76 to 1.21); and for death from cancer (341 deaths from cancer), 0.97 (95% CI, 0.79 to 1.20). In the analysis of death from any cause (978 deaths overall), the hazard ratio was 1.02 (95% CI, 0.90 to 1.15). No excess risks of bleeding or other serious adverse events were observed. CONCLUSIONS: Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“although only REDUCE-IT has shown cardiovascular benefits (as discussed later) (14-17).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“butseverallargeclinicaltrialsfailed to demonstrate any cardiovascular benefit with administration of low doses of omega-3 fatty acids. 8,12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TheVitaminDandOmega-3Trial(VITAL), in which 13% of the participants had type 2 diabetes, supplementation with 1 g of omega-3 fatty acids did not result in a lower incidence of major cardiovascular events (305).”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [305]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials revealed that ω3 PUFA supplementation of <1 g/d resulted in a very limited reduction in atherosclerotic CVD risk of major vascular events and CVD‐caused deaths. 22 , 23 , 133 , 154”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies showed inconsistent reductions in MACE.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple large studies conducted since then to examine the benefits of low-dose mixtures of EPA and DHA with more contemporary background therapy, including statin therapy, have failed to show any significant reduction in cardiovascular endpoints.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, other recent trials studying lower doses of omega-3 fatty acids in a broader range of patients failed to demonstrate significant reductions of total cardiovascular events. 12,13”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This may explain why EPA + DHA combination treatment in various trials did not demonstrate an effect on reducing cardiovascular risk. 23 , 24 , 25 , 133”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Earlier trials such as GISSI-Prevenzione, ASCEND, VITAL, and OMEMI evaluated low-dose EPA/DHA mixtures primarily in primary prevention settings or post-MI patients, often without significant baseline TG elevation and with limited use of statins in earlier trials [87–90].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ASCEND (A Study of Cardiovascular Events in Diabetes) [3] and VITAL (Vitamin D and Omega-3 Trial) trials [5] using EPA+DHA did not signi fi cantly reduce the primary cardiovascular endpoints”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“During a median follow-up of 5.3 years, there was no significant difference in the 2 primary endpoints of major cardiovascular events (a composite of MI, stroke, or death from cardiovascular causes) or invasive cancer of any type.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [16]
In the citing paper
“Contemporary studies were conducted with higher standards and consistently failed to demonstrate significant benefits.”
In the citing paper
“at lower doses (1 g/day) these agents have generally failed to show reduced ASCVD.50,51”
From Clinical review on triglycerides (2020) · cites this paper as [51]
In the citing paper
“Recently, a new selective PPAR-α modulator (pemafibrate) has been reported to have marked efficacy in reducing TRLs [317].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [317]
In the citing paper
“However, this trial showed that just 840 mg of combined EPA/DHA significantly reduced MI and major CHD events [63].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“This study did not show that supplementing with n-3 fatty acids reduced the incidence of major CVD events (a composite of MI, stroke, and death from CVD causes) or invasive cancer.”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [63]
In the citing paper
“Individuals with low baseline fish consumption (<1.5 servings/week) had decreased risk for total CV events (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.67 to 0.98).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“However, there was a 28% reduction in total MI, which emerged after the first year and continued throughout the trial.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the VITAL trial, omega-3 PUFAs did not significantly reduce the primary composite endpoint of major ASCVD events (MI, stroke, and CVD mortality).”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“Black study participants experienced a 77% treatment-associated reduction in MI (HR: 0.23; 95% CI: 0.11 to 0.47), and derived an MI benefit irrespective of baseline fish intake.”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“There were significant reductions in other pre-specified secondary outcomes, including a 17% reduced risk for total coronary heart disease (CHD) and a 50% reduction in fatal MI”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [61]
In the citing paper
“In the statin era, CVOTs of combination OM-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] have not shown reduction in cardiovascular disease (CVD) events.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“Additional factors that may influence CVOT findings include OM-3 dose, definition of primary composite CV endpoint, and study population.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The total daily dose of OM-3 was much lower in VITAL and ASCEND (< 1 g/day total OM-3 per each 1-g capsule) than in REDUCE-IT (4 g/day high-purity Rx EPA).”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“The primary composite CV endpoint varied between the studies (Table 1, see footnote); for example, in REDUCE-IT, coronary revascularization and unstable angina were included, in addition to CV death, nonfatal myocardial infarction, and nonfatal stroke.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [11]
In the citing paper
“A 17% risk reduction was recorded for total coronary heart disease, versus placebo.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Indeed, while the primary outcome of the study, a reduction in major cardiovascular events (a composite of myocardial infarction, stroke, and death from cardiovascular causes), was not achieved with statistical significance, the analysis did demonstrate an 8% reduction in such events.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“Interestingly for African-Americans, the study found a dramatic 77% reduction in heart attacks linked to daily omega-3 supplementation.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“In people who do not consume the recommended 1 or 2 servings of fish a week, the n-3 LCPUFA supplementation was linked to a 40% reduction in heart attacks; however, among the subjects who followed the fish consumption recommendation, there was no such association.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“The primary conclusion of the VITAL study was not positive regarding the effect of supplementation with n-3 LCPUFA on major cardiovascular events as the data failed to show a lower incidence of major cardiovascular events in the experimental group than in the placebo control group [53].”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
In the citing paper
“However, the secondary outcomes were highly relevant as omega-3 supplementation was associated with a reduction in total and fatal myocardial infarction risk by 28% and 50%, respectively.”
From Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations (2021) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,350
Self-citationPrevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Third universal definition of myocardial infarction
the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., CHAITMAN, B. R., & White, H. D. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.122 · Cited by 6,585
Isolated Hand Paresis: A Case Series
Alstadhaug, K. B., & Sjulstad, A. S. (2013) · Cerebrovascular Diseases Extra · doi:10.1159/000350708 · Cited by 4,090
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., & White, H. D. (2012) · Circulation · doi:10.1161/cir.0b013e31826e1058 · Cited by 2,985
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes
Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., Dietrich, T., & Dawson-Hughes, B. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.18 · Cited by 2,414
Self-citationPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Rimm, E. B., Giovannucci, E. L., Stampfer, M. J., Colditz, G. A., Litin, L. B., & Willett, W. C. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116211 · Cited by 2,104
Self-citation(1999) · PubMed · Cited by 2,062
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Estimates of optimal vitamin D status
Dawson‐Hughes, B., Heaney, R. P., Holick, M. F., Lips, P. T. A. M., Meunier, P. J., & Vieth, R. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1867-7 · Cited by 1,852
Omega-3 Fatty Acids and Cardiovascular Disease
Mozaffarian, D., & Wu, J. H. Y. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.063 · Cited by 1,771
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Manson, J. E., Cook, N. R., Lee, I.-M. M., Christen, W., Bassuk, S. S., Mora, S., Luttmann‐Gibson, H., Gordon, D., Copeland, T., D’Agostino, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809944 · Cited by 1,684
Self-citationVitamin D and calcium supplementation reduces cancer risk: results of a randomized trial
Lappe, J. M., Travers‐Gustafson, D., Davies, K. M., Recker, R. R., & Heaney, R. P. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.6.1586 · Cited by 1,445
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Simopoulos, A. P. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.07.080 · Cited by 1,143
Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H. A., Johnson, L., Franco, O. H., Butterworth, A. S., Forouhi, N. G., Thompson, S. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1788 · Cited by 1,139
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
Feskanich, D., Rimm, E. B., Giovannucci, E. L., Colditz, G. A., Stampfer, M. J., Litin, L. B., & Willett, W. C. (1993) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(93)91754-e · Cited by 1,070
Self-citationProspective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men
Giovannucci, E. L., Liu, Y., Rimm, E. B., Hollis, B. W., Fuchs, C. S., Stampfer, M. J., & Willett, W. C. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj101 · Cited by 1,041
Self-citationPolyunsaturated fatty acids in the food chain in the United States
Kris-Etherton, P., Taylor, D. S., Yu-Poth, S., Huth, P., Moriarty, K., Fishell, V., Hargrove, R. L., Zhao, G., & Etherton, T. D. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.1.179s · Cited by 1,023
Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer
Wactawski‐Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O’Sullivan, M. J., Margolis, K. L., Ockene, J. K., Phillips, L. S., Pottern, L. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055222 · Cited by 980
Self-citationRizos, E. C., Ntzani, E. E., Bika, E., Kostapanos, M. S., & Elisaf, M. S. (2012) · JAMA · doi:10.1001/2012.jama.11374 · Cited by 960
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Hathcock, J. N., Shao, A. E., Vieth, R., & Heaney, R. P. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.1.6 · Cited by 883
Martins, D., Wolf, M. S., Pan, D., Zadshir, A., Tareen, N. G., Thadhani, R., Felsenfeld, A. J., Levine, B. S., Mehrotra, R., & Norris, K. C. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.11.1159 · Cited by 832
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L. J., Banka, C. L., Benjamin, E. J., Berra, K. A., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 753
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 722
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
The urgent need to recommend an intake of vitamin D that is effective
Vieth, R., Bischoff-Ferrari, H. A., Boucher, B. J., Dawson‐Hughes, B., Garland, C. F., Heaney, R. P., Holick, M. F., Hollis, B. W., Lamberg-Allardt, C. J. E., McGrath, J. J., et al. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.649 · Cited by 684
Self-citationOmega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 647
Trends in dietary supplement use among US adults from 1999-2012.
Kantor, E. D., Rehm, C. D., Du, M., White, E., & Giovannucci, E. L. (2016) · JAMA · doi:10.1001/jama.2016.14403 · Cited by 644
Self-citationAung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632
Siscovick, D. S., Barringer, T. A., Fretts, A. M., Wu, J. H. Y., Lichtenstein, A. H., Costello, R. B., Kris-Etherton, P. M., Jacobson, T. A., Engler, M. B., Alger, H. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000482 · Cited by 629
Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Manson, J. E., Bassuk, S. S., Lee, I.-M. M., Cook, N. R., Albert, M. A., Gordon, D., Zaharris, E., MacFadyen, J. G., Danielson, E., Lin, J., et al. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.09.009 · Cited by 559
Self-citationRobust Variance Estimation for the Case-Cohort Design
Barlow, W. E. (1994) · Biometrics · doi:10.2307/2533444 · Cited by 542
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519
Greenlandic Inuit show genetic signatures of diet and climate adaptation
Fumagalli, M., Moltke, I., Grarup, N., Racimo, F., Bjerregaard, P., Jørgensen, M. E., Korneliussen, T. S., Gerbault, P., Skotte, L., Linneberg, A. R., et al. (2015) · Science · doi:10.1126/science.aab2319 · Cited by 519
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Rimm, E. B., Appel, L. J., Chiuve, S. E., Djoussé, L., Engler, M. B., Kris-Etherton, P. M., Mozaffarian, D., Siscovick, D. S., Lichtenstein, A. H., & On behalf of the American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology (2018) · Circulation · doi:10.1161/cir.0000000000000574 · Cited by 500
Interplay Between Different Polyunsaturated Fatty Acids and Risk of Coronary Heart Disease in Men
Mozaffarian, D., Ascherio, A., Hu, F. B., Stampfer, M. J., Willett, W. C., Siscovick, D. S., & Rimm, E. B. (2005) · Circulation · doi:10.1161/01.cir.0000152099.87287.83 · Cited by 464
Self-citationGalan, P., Kesse-Guyot, E., Czernichow, S., Briancon, S., Blacher, J., Hercberg, S., & for the SU.FOL.OM3 Collaborative Group (2010) · BMJ · doi:10.1136/bmj.c6273 · Cited by 457
Antioxidant Vitamin Supplements and Cardiovascular Disease
Kris‐Etherton, P. M., Lichtenstein, A. H., Howard, B. V., Steinberg, D. H., & Witztum, J. L. (2004) · Circulation · doi:10.1161/01.cir.0000137822.39831.f1 · Cited by 409
Del Gobbo, L. C., Imamura, F., Aslibekyan, S., Marklund, M., Virtanen, J. K., Wennberg, M., Yakoob, M. Y., Chiuve, S. E., dela Cruz, L., Frazier-Wood, A. C., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2925 · Cited by 404
Self-citationVitamin D and African Americans
Harris, S. S. (2006) · Journal of Nutrition · doi:10.1093/jn/136.4.1126 · Cited by 381
Feskanich, D., Willett, W. C., & Colditz, G. A. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.2.504 · Cited by 358
Self-citationVitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration
Aloia, J. F., Patel, M. R., DiMaano, R., Li‐Ng, M., Talwar, S. A., Mikhail, M., Pollack, S. Z., & Yeh, J. K. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.6.1952 · Cited by 333
Martinelli, N., Girelli, D., Malerba, G., Guarini, P., Illig, T., Trabetti, E., Sandri, M. F., Friso, S., Pizzolo, F., Schaeffer, L., et al. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.4.941 · Cited by 332
Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
Brasky, T. M., Darke, A. K., Song, X., Tangen, C. M., Goodman, P. J., Thompson, I. M., Meyskens, F. L., Goodman, G. E., Minasian, L. M., Parnes, H. L., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt174 · Cited by 307
Jacques, P. F., Sulsky, S., Sadowski, J., Phillips, J., Rush, D., & Willett, W. C. (1993) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/57.2.182 · Cited by 306
Self-citationHunter, D. J., Rimm, E. B., Sacks, F. M., Stampfer, M. J., Colditz, G. A., Litin, L. B., & Willett, W. C. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116302 · Cited by 277
Self-citationTissue n−3 and n−6 fatty acids and risk for coronary heart disease events
Harris, W. S., Poston, W. C., & Haddock, C. K. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.018 · Cited by 271
Alexander, D. D., Miller, P. E., Elswyk, M. E. V., Kuratko, C. N., & Bylsma, L. C. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.10.018 · Cited by 262
Omega-3 Fatty Acids for Cardioprotection
Lee, J. H., O’Keefe, J. H., Lavie, C. J., Marchioli, R., & Harris, W. S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.324 · Cited by 251
Safety Considerations with Omega-3 Fatty Acid Therapy
Bays, H. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.020 · Cited by 235
Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies
Gerber, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001614 · Cited by 211
Vitamin D Intakes by Children and Adults in the United States Differ among Ethnic Groups
Moore, C. E., Murphy, M. M., & Holick, M. F. (2005) · Journal of Nutrition · doi:10.1093/jn/135.10.2478 · Cited by 207
Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners
Geller, N. L., & Pocock, S. (1987) · Biometrics · doi:10.2307/2531962 · Cited by 202
VITAMIN D IN HEALTH AND DISEASE: Vitamin D for Health and in Chronic Kidney Disease
Holick, M. F. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.18402.x · Cited by 189
Bardia, A., Tleyjeh, I. M., Cerhan, J. R., Sood, A., Limburg, P. J., Erwin, P. J., & Montori, V. M. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.23 · Cited by 185
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167
The omega-6/omega-3 ratio and cardiovascular disease risk: Uses and abuses
Harris, W. S. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0019-7 · Cited by 157
Bonds, D. E., Harrington, M., Worrall, B. B., Bertoni, A. G., Eaton, C. B., Hsia, J., Robinson, J., Clemons, T. E., Fine, L. J., & Chew, E. Y. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.328 · Cited by 118
Dose response to vitamin D supplementation among postmenopausal African American women
Talwar, S. A., Aloia, J. F., Pollack, S. Z., & Yeh, J. K. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.5.1657 · Cited by 114
Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL)
Bassuk, S. S., Manson, J. E., Lee, I.-M. M., Cook, N. R., Christen, W. G., Bubes, V. Y., Gordon, D., Copeland, T., Friedenberg, G., D’Agostino, D., et al. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.12.022 · Cited by 101
Self-citationHarris, S. S., & Dawson‐Hughes, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0722 · Cited by 90
Tong, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.05.014 · Cited by 87
Bordeleau, L. J., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J. L., Yu, P. C., Rydén, L., Pīrāgs, V., Spinas, G. A., Birkeland, K. I., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1468 · Cited by 86
Current controversies in data monitoring for clinical trials
Pocock, S. (2006) · Clinical Trials · doi:10.1177/1740774506073467 · Cited by 82
International recommendations for consumption of long-chain omega-3 fatty acids
Harris, W. S. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/01.jcm.0000289274.64933.45 · Cited by 73
Vitamin D and Cancer: Current Dilemmas and Future Needs
Davis, C. D., Hartmuller, V. W., Freedman, D. M., Hartge, P. A., Picciano, M. F., Swanson, C. A., & Milner, J. A. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.aug.s71-s74 · Cited by 47
The Omega Diet: The Lifesaving Nutritional Program Based on the Diet of the Island of Crete
Simopoulos, A. P., & Robinson, J. A. (1999) · Medical Entomology and Zoology · Cited by 45
Zhang, Y.-F., Gao, H.-F., Hou, A., & Zhou, Y. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-204 · Cited by 45
Andreeva (2012) · doi:10.1001/archinternmed.2011.1450 · Cited by 40
Biochemical Markers of Compliance in the Physicians’ Health Study
Satterfield, S., Greco, P. J., Goldhaber, S. Z., Stampfer, M. J., Swartz, S. L., Stein, E. A., Kaplan, L. A., & Hennekens, C. H. (1990) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30997-8 · Cited by 40
Giovannucci, E. L. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00345.x · Cited by 39
Self-citationThe "Sunshine Vitamin": Benefits Beyond Bone?
Davis, C. D., & Dwyer, J. T. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm211 · Cited by 37
Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?
Rizos, E. C., & Elisaf, M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0856-8 · Cited by 31
Peng, T. (2008) · PubMed · Cited by 1
Stampfer, M. J. (2006) · PubMed · Cited by 1
Multiple imputation of missing blood pressure covariates in survival analysis
van Buuren, S., Boshuizen, H. C., & Knook, D. L. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Metadata
- Authors
- Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., D’Agostino, D., Friedenberg, G., Ridge, C., Bubes, V., Giovannucci, E. L., Willett, W. C., & Buring, J. E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (J.E.M., N.R.C., I-M.L., W.C., S.S.B., S.M., H.G., C.M.A., D.G., T.C., D.D., G.F., C.R., V.B., E.L.G., W.C.W., J.E.B.), and the Departments of Epidemiology (J.E.M., N.R.C., I.-M.L., W.C.W., J.E.B.) and Nutrition (E.L.G., W.C.W.), Harvard T.H. Chan School of Public Health — all in Boston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6392053
- OpenAlex
- W2899720772
- Semantic Scholar
- bb3183c85d8686140abdf23d14174712153d2ed2
- Cited by
- 979
- References
- 94
- Citations by year
- 2026: 78 · 2025: 93 · 2024: 98 · 2023: 121 · 2022: 130 · 2021: 136 · 2020: 162 · 2019: 141
- FWCI
- 94.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R0 CA138962)
- National Cancer Institute
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
- Keywords
- omega-3 fatty acids, cardiovascular disease prevention, cancer prevention, primary prevention, cardiovascular events, myocardial infarction, stroke, cancer mortality, coronary revascularization, dietary supplementation, cardiovascular risk reduction, cancer risk reduction, older adults, Black participants, cancer risk factors
- MeSH terms
- Aged, Cardiovascular Diseases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms, Fatty Acids, Omega-3, Incidence, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
